BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 30539282)

  • 1. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
    Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
    Sun F; Zhao R; Zhu Y; Cui D; Wang X; Han B; Liang S; Liu H; Sun X; Zhao F; Xu D; Xia S
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1099-1107. PubMed ID: 28421294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
    Huang B; Zheng J; Yao Z; Fan W; Qiu S; Chen L; Chen J
    World J Urol; 2019 May; 37(5):823-829. PubMed ID: 30191393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer.
    Kato T; Nomura K; Kondo F; Wakisaka M; Komiya A
    ScientificWorldJournal; 2015; 2015():325305. PubMed ID: 26101785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
    Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
    Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
    Yang GL; Zhang LH; Liu Q; Wang ZL; Duan XH; Huang YR; Bo JJ
    Urol Oncol; 2017 Feb; 35(2):38.e9-38.e15. PubMed ID: 28040419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.
    Onozawa M; Miyanaga N; Hinotsu S; Miyazaki J; Oikawa T; Kimura T; Takaoka E; Kawai K; Shimazui T; Sakurai H; Nishiyama H; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):825-30. PubMed ID: 22782963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression.
    Chen MK; Qin ZK; Zhou FJ; Han H; Liu ZW; Li YH; Yao K; Hou GL; Ye YL; Zhang ZL; Tu H; Zhang XQ; Lu KS; Yang ZW
    J Chemother; 2009 Dec; 21(6):681-6. PubMed ID: 20071293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
    Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.